Recent global market activity has been marked by a rotation away from large-cap growth stocks, driven by inflation concerns and the sell-off in AI-related sectors. In this context, penny stocks—often smaller or newer companies—remain an intriguing option for investors seeking potential value at lower price points. Despite the term's vintage feel, these stocks can offer surprising opportunities when backed by solid financial foundations and strong balance sheets.
Below we spotlight a couple of our favorites from our exclusive screener.
XJ International Holdings (SEHK:1765)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: XJ International Holdings Co., Ltd. is an investment holding company that provides higher education and secondary vocational education services in China, Malaysia, Thailand, and Hungary with a market cap of HK$1.10 billion.
Operations: The company generates revenue from two main segments: Global Education, contributing CN¥756.70 million, and Domestic Education, which accounts for CN¥3.20 billion.
Market Cap: HK$1.1B
XJ International Holdings has shown stable weekly volatility at 7% over the past year, with a significant one-off gain of CN¥961.6 million impacting recent financial results. Despite this, its earnings growth of 0.6% underperformed the industry average of 6.8%. The board and management team are relatively inexperienced, averaging tenures of 2.8 and 1.2 years respectively. While short-term liabilities exceed short-term assets by CN¥900 million, long-term liabilities are well-covered by assets totaling CN¥4 billion against CN¥3.1 billion in obligations. The company's debt is well-managed with a net debt to equity ratio at a satisfactory 4%.
- Click here and access our complete financial health analysis report to understand the dynamics of XJ International Holdings.
- Assess XJ International Holdings' previous results with our detailed historical performance reports.
HighTide Therapeutics (SEHK:2511)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: HighTide Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for chronic metabolic and liver diseases in Mainland China, with a market cap of HK$1.80 billion.
Operations: HighTide Therapeutics, Inc. does not have any reported revenue segments at this time.
Market Cap: HK$1.8B
HighTide Therapeutics, Inc., a clinical-stage biopharmaceutical firm, is pre-revenue with earnings yet to materialize. Despite this, the company maintains a favorable financial position with short-term assets of CN¥368.9 million surpassing both its short-term and long-term liabilities. The firm's cash reserves exceed its total debt, providing a sufficient runway for over a year based on current free cash flow trends. However, the stock has shown high volatility recently and remains unprofitable with losses increasing to CN¥146.1 million for the first half of 2026 compared to CN¥120.32 million in the previous year.
- Unlock comprehensive insights into our analysis of HighTide Therapeutics stock in this financial health report.
- Gain insights into HighTide Therapeutics' historical outcomes by reviewing our past performance report.
Puyang Refractories Group (SZSE:002225)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Puyang Refractories Group Co., Ltd. is involved in the research, development, production, and sales of shaped, unshaped, and functional refractory products both in China and internationally, with a market capitalization of approximately CN¥3.75 billion.
Operations: No specific revenue segments are reported for Puyang Refractories Group Co., Ltd.
Market Cap: CN¥3.75B
Puyang Refractories Group Co., Ltd. reported a decline in net income to CN¥30.15 million for the nine months ended September 30, 2026, down from CN¥94.87 million a year prior. Despite stable revenue of CN¥4,077.4 million, profit margins fell to 0.4% from 2%. The company’s short-term assets of CN¥6.4 billion comfortably cover both short and long-term liabilities; however, operating cash flow is insufficient to cover its debts effectively. Earnings have been negatively impacted by large one-off items and have declined consistently over five years, with the debt-to-equity ratio increasing to 48.2%.
- Get an in-depth perspective on Puyang Refractories Group's performance by reading our balance sheet health report here.
- Review our historical performance report to gain insights into Puyang Refractories Group's track record.
Turning Ideas Into Actions
- Unlock more gems! Our Global Penny Stocks screener has unearthed 3,670 more companies for you to explore.Click here to unveil our expertly curated list of 3,673 Global Penny Stocks.
- Ready To Venture Into Other Investment Styles? We've found 9 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com